Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475277 · ClinicalTrials.gov registry record
Stanford Regulating Circuits of the Brain Study- Ketamine
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 13
- Enrollment target
NCT03475277: Completed study, sponsored by Stanford University.
NCT03475277 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03475277 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This study is a biomarker study designed to characterize how ketamine impacts the reward circuits of the human brain.
Primary Outcome
During functional magnetic resonance imaging the reward and negative affect circuits will be engaged by reward and related emotional tasks, and circuit activation will be quantified by blood flow in regions of interest and the extent of functional connectivity between them
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2024-07-01 |
What the finished NCT03475277 record still lists
NCT03475277 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT03475277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03475277 about?
NCT03475277 is a clinical study titled "Stanford Regulating Circuits of the Brain Study- Ketamine". This study is a biomarker study designed to characterize how ketamine impacts the reward circuits of the human brain.
What is the current status of trial NCT03475277?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2019-08-19. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT03475277?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT03475277?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI